LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Efficacy of tyrosine-kinase-2 and phosphodiesterase-4 inhibitors for scalp psoriasis: a systematic review and meta-analysis.

    Tsiogkas, Sotirios G / Karamitrou, Eleni K / Grammatikopoulou, Maria G / Zafiriou, Efterpi / Bogdanos, Dimitrios P

    Current medical research and opinion

    2024  Volume 40, Issue 2, Page(s) 155–163

    Abstract: Objectives: Psoriasis of the scalp is challenging to manage. The only approved oral tyrosine kinase 2 and phosphodiesterase 4 inhibitors for psoriasis are deucravacitinib and apremilast. The aim of this study was to explore their efficacy for scalp ... ...

    Abstract Objectives: Psoriasis of the scalp is challenging to manage. The only approved oral tyrosine kinase 2 and phosphodiesterase 4 inhibitors for psoriasis are deucravacitinib and apremilast. The aim of this study was to explore their efficacy for scalp psoriasis utilizing data from randomized controlled trials.
    Methods: We searched Medline, Scopus, Web of Science, CENTRAL, and ClinicalTrials.gov up to August 4, 2023. To determine risk of bias, the revised Risk of Bias assessment tool 2.0 was used. Inverse variance random effects meta-analyses were executed. Heterogeneity was assessed utilizing Q and I
    Results: Ten RCTs fulfilled inclusion criteria. Both apremilast (RR = 2.41, 95% CI = 2.08-2.79, Tau
    Conclusions: Apremilast and deucravacitinib are effective for scalp psoriasis. Deucravacitinib may be more efficient in clearing the scalp.
    MeSH term(s) Humans ; Phosphodiesterase 4 Inhibitors/therapeutic use ; Cyclic Nucleotide Phosphodiesterases, Type 4/therapeutic use ; TYK2 Kinase/therapeutic use ; Scalp ; Psoriasis/drug therapy ; Tyrosine/therapeutic use ; Severity of Illness Index ; Treatment Outcome ; Randomized Controlled Trials as Topic ; Thalidomide/analogs & derivatives
    Chemical Substances apremilast (UP7QBP99PN) ; Phosphodiesterase 4 Inhibitors ; Cyclic Nucleotide Phosphodiesterases, Type 4 (EC 3.1.4.17) ; TYK2 Kinase (EC 2.7.10.2) ; Tyrosine (42HK56048U) ; Thalidomide (4Z8R6ORS6L)
    Language English
    Publishing date 2024-01-24
    Publishing country England
    Document type Meta-Analysis ; Systematic Review ; Journal Article
    ZDB-ID 80296-7
    ISSN 1473-4877 ; 0300-7995
    ISSN (online) 1473-4877
    ISSN 0300-7995
    DOI 10.1080/03007995.2023.2288280
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 955: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Early menopause and premature ovarian insufficiency are associated with increased risk of dementia: A systematic review and meta-analysis of observational studies.

    Karamitrou, Eleni K / Anagnostis, Panagiotis / Vaitsi, Konstantina / Athanasiadis, Loukas / Goulis, Dimitrios G

    Maturitas

    2023  Volume 176, Page(s) 107792

    Abstract: Background/aims: Among other risk factors, the decline in estrogen concentrations during menopause may compromise cognitive function. Whether early menopause (EM) is associated with an increased risk of dementia remains unclear. The purpose of this ... ...

    Abstract Background/aims: Among other risk factors, the decline in estrogen concentrations during menopause may compromise cognitive function. Whether early menopause (EM) is associated with an increased risk of dementia remains unclear. The purpose of this study was to systematically review and meta-analyze current evidence regarding the association between EM or premature ovarian insufficiency (POI) and the risk of dementia of any type.
    Materials and methods: A comprehensive literature search was conducted through the PubMed, Scopus and CENTRAL databases up to August 2022. Study quality was assessed using the Newcastle-Ottawa scale. Associations were calculated as odds ratio (OR) with 95 % confidence interval (CI). The I
    Results: Eleven studies (nine assessed as of good and two as of fair quality) were included in the meta-analysis (n = 4,716,862). Women with EM demonstrated a greater risk of dementia of any type than women of normal age at menopause (OR 1.37, 95 % CI 1.22-1.54; I
    Conclusions: Women with EM or POI may be at increased risk of dementia compared with women of normal age at menopause, but further research investigating that hypothesis is warranted.
    MeSH term(s) Female ; Humans ; Retrospective Studies ; Menopause, Premature ; Primary Ovarian Insufficiency/complications ; Menopause ; Dementia/complications
    Language English
    Publishing date 2023-06-23
    Publishing country Ireland
    Document type Meta-Analysis ; Systematic Review ; Journal Article ; Review
    ZDB-ID 80460-5
    ISSN 1873-4111 ; 0378-5122
    ISSN (online) 1873-4111
    ISSN 0378-5122
    DOI 10.1016/j.maturitas.2023.107792
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1432: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 575: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top